

RAF709

## Chemical Properties


CAS No. : 1628838-42-5

Formula: C<sub>28</sub>H<sub>29</sub>F<sub>3</sub>N<sub>4</sub>O<sub>4</sub>

Molecular Weight: 542.55

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



## Biological Description

Description	RAF709 is a novel Raf kinase inhibitor with IC <sub>50</sub> s of 0.5 and 1.8 nM for c-Raf and b-Raf, respectively.
Targets(IC <sub>50</sub> )	Raf
In vitro	The invention provides compounds (e.g., RAF709) that inhibit Raf kinases, and are accordingly useful for treating certain disorders associated with excessive Raf kinase activity, including cell proliferation disorders such as cancers[1].

## Solubility Information

Solubility	DMSO: 91 mg/mL (167.73 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (6.08 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

---

	1mg	5mg	10mg
1 mM	1.8431 mL	9.2157 mL	18.4315 mL
5 mM	0.3686 mL	1.8431 mL	3.6863 mL
10 mM	0.1843 mL	0.9216 mL	1.8431 mL
50 mM	0.0369 mL	0.1843 mL	0.3686 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Robert AVERSA, et al. Biaryl amide compounds as kinase inhibitors. WO2014151616A1.

Wang X, Wu F, Wang H, et al. PDCD6 cooperates with C-Raf to facilitate colorectal cancer progression via Raf/MEK/ERK activation. Journal of Experimental & Clinical Cancer Research. 2020, 39(1): 1-15

Wang X, Wu F, Wang H, et al. PDCD6 cooperates with C-Raf to facilitate colorectal cancer progression via Raf/MEK/ERK activation[J]. Journal of Experimental & Clinical Cancer Research. 2020, 39(1): 1-15.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481